Editorial

A look back at 3 years of neurological research and practice (NRP)

Werner Hacke*

In March 2019, we launched Neurological Research and Practice (NRP), the official English language, open access, online journal of the German Society of Neurology (Deutsche Gesellschaft für Neurologie) [1]. Each year, I have reported on the new journal’s progress [2, 3]. In our third year, it’s time again to summarize what we’ve achieved and what’s about to come.

I’m proud to say that we have achieved several significant milestones. First, NRP has now published more than 150 peer-reviewed articles. As submissions have increased, our acceptance rate has dropped from around 60% to below 40%. While most articles originate from Germany, about 30% have first authors and affiliations from outside the country. This number has also increased over the years.

Second, last year NRP was listed in PubMed®, a major accomplishment for a journal less than three years after its first publication. PubMed® was largely responsible for the remarkable increase in full article downloads (Fig. 1) and international visits to the journal’s website (Fig. 2). These two graphs show how access to our articles has continuously grown and from which global regions they are being made. The international visits are impressive. Surprisingly, the number of hits from Germany is relatively low compared with the numbers from the U.S., Great Britain, and India.

Third, the citation of articles is still one of the most prominent aspects of the impact and visibility of a journal. For NRP, the citation rates are quite good, especially for a new journal. Table 1 lists the most cited articles from 2019 and 2020 (with reference numbers). The most frequently cited were not only research articles and reviews but also guidelines, SOPs, letters, and a clinical trial protocol indicating that readers found valuable information in a wide range of our publication categories. Another important feature is the number of article accesses. Table 2 lists articles with more than 7000 accesses. The most accessed article already has more than 150,000 accesses (there’s some overlap with the most cited articles, but Table 2 includes more articles from 2021, and the most accessed articles were not necessarily the most cited ones).

One of the next milestones we are looking forward to is NRP becoming indexed in the Emerging Sources Citation Index produced by Clarivate Analytics. Becoming indexed would further improve the journal’s visibility and contribute to its Impact Factor. After just three years in operation, this would be a major achievement. Let’s keep our fingers crossed that I will be able to report on that next year.

At the beginning of 2022, after 3 years of me being the sole editor of the Journal, we appointed section editors for different scientific areas (you can find a list of section editors on the website starting page. https://neurorespact.biomedcentral.com). The section editors, international editorial board members, and many other colleagues have supported NRP as authors and reviewers. Our single, blinded peer review protocol requires at least two and sometimes more reviews. As we all know, it’s getting increasingly difficult to find qualified reviewers who commit to the swift delivery of high-quality reviews, especially for a new journal. Unfortunately, Data Protection Regulations prevent us from listing the reviewers who supported the Journal...
Fig. 1 Successful full-article downloads

Source: COUNTER usage data on Google BigQuery. Downloads from SpringerLink, nature.com and BMC Platform.

Fig. 2 Visits by geography

Source: Google Analytics data on Google Big Query.
and express our gratefulness for their work. Some of the quick and reliable reviewers have been invited frequently and contributed a lot. The list is led by 5 colleagues, who contributed more than 15 Reviews. These are Christos Krogias [22] from Bochum, Simon Nagel from Heidelberg, now Ludwigshafen [16]. Uta Meyding-Lamade from Frankfurt [20], Ralf Linker from Regensburg [17], and Julian Bösel from Kassel [15]. These colleagues have agreed to the publication of their names. In order to acknowledge the contributions of our reviewers we will create a regularly updated Top reviewers list on the journals webpage for further reference. Unfortunately, we also had some colleagues on the editorial board and in our growing list of potential reviewers who never responded, declined every invitation, or did not deliver although they initially agreed to review. However, this is not specific to our journal, and I hear that from several fellow editors of other international journals. Spam filters and hospital firewalls may be partially responsible for that.

All in all, we have had a very rewarding first 3 years of the journal. Once we receive an Impact Factor, we can declare that NRP is out of “early childhood” and about to enter the next phase of its development.

Thank you to all who supported this endeavor and helped with a successful takeoff.

### Table 1 Highly cited articles (> 10 citations)

| References       | Year | Citations | Type |
|------------------|------|-----------|------|
| Dziewas et al.   | 2019 | 41        | res  |
| Berlit et al.    | 2020 | 35        | gui  |
| Greffkes and Fink| 2019 | 30        | rev  |
| Weber et al.     | 2019 | 30        | res  |
| Mokli et al.     | 2019 | 28        | rev  |
| Busetto et al.   | 2020 | 28        | rev  |
| Lehmann et al.   | 2020 | 20        | sop  |
| Lampe et al.     | 2020 | 17        | let  |
| Prasuhn et al.   | 2019 | 14        | tri  |
| Sembill et al.   | 2019 | 13        | rev  |
| Göttle et al.    | 2019 | 12        | rev  |
| Schlereth        | 2020 | 12        | gui  |
| Berg et al.      | 2019 | 12        | gui  |
| Eyding et al.    | 2019 | 11        | res  |
| Marsh            | 2019 | 11        | rev  |

gui, guideline; let, letter; res, research article; rev, review; sop, standard operating procedure; tri, trial protocol

### Table 2 Top 20 accesses > 7000

| References       | Year | Accesses |
|------------------|------|----------|
| Busetto et al.   | 2020 | 169,000  |
| Berlit et al.    | 2020 | 34,000   |
| Werner et al.    | 2020 | 24,000   |
| Greffkes et al.  | 2020 | 19,000   |
| Lehmann et al.   | 2020 | 19,000   |
| Sembill et al.   | 2019 | 15,000   |
| Gövert et al.    | 2020 | 14,000   |
| Mokli et al.     | 2019 | 9,500    |
| Bien and Bien    | 2020 | 8,600    |
| Schlereth et al. | 2020 | 8,500    |
| Stetefeld and Schroeter | 2019 | 8,000 |
| Grobe-Einsler and Kaut | 2020 | 8,000 |
| Ganti et al.     | 2019 | 7,600    |
| Meyding-Lamade et al. | 2019 | 7,400 |
| Walter and Kremer| 2021 | 7,200    |
| Stefanou et al.  | 2019 | 7,100    |
| Rössling and Prüss| 2020 | 7,000  |

gui, guideline; let, letter; res, research article; rev, review; sop, standard operating procedure; tri, trial protocol

### Author contributions

The author(s) read and approved the final manuscript.

### Declarations

#### Competing interests

WH is the Editor in Chief of Neurological research and Practice, appointed by the German Neurological Society (Deutsche Gesellschaft für Neurologie, and receives a modest annual renumeration for the time invested. No further competing interests to be declared.

### References

1. Hacke, W. (2019). Announcing the new launch of Neurological Research and Practice. Neurological Research and Practice, 1, 7.
2. Hacke, W. (2020). Neurological research and practice: The first year. Neurological Research and Practice, 2, 5.
3. Hacke, W. (2021). Neurological research and practice: the first milestone has been reached. Neurological Research and Practice, 3, 3.
4. Dziewas, R., auf dem Brinke, M., Birkmann, U., et al. (2019). Safety and clinical impact of FEES—Results of the FEES-registry. Neurological Research and Practice, 1, 16.
5. Berlit, F., Bösel, J., Gahn, G., et al. (2020). “Neurological manifestations of COVID-19”—Guideline of the German society of neurology. Neurological Research and Practice, 2, 51.
6. Greffkes, C., & Fink, G. R. (2020). Recovery from stroke: Current concepts and future perspectives. Neurological Research and Practice, 2, 17.
7. Weber, R., Eyding, J., Kitzrow, M., et al. (2019). Distribution and evolution of acute interventional ischemic stroke treatment in Germany from 2010 to 2016. Neurological Research and Practice, 1, 4.
8. Mokli, Y., Pfaff, J., dos Santos, D. P, et al. (2019). Computer-aided imaging analysis in acute ischemic stroke—Background and clinical applications. Neurological Research and Practice, 1, 23.
9. Busetto, L., Wick, W., & Gumbinger, C. (2020). How to use and assess qualitative research methods. *Neurological Research and Practice, 2*, 14.

10. Lehmann, H. C., Wunderlich, G., Fink, G. R., et al. (2020). Diagnosis of peripheral neuropathy. *Neurological Research and Practice, 2*, 20.

11. Lampe, A., Winschel, A., Lang, C., et al. (2020). Guillain–Barré syndrome and SARS-CoV-2. *Neurological Research and Practice, 2*, 19.

12. Sembii, J. A., Kuramatsu, J. B., Schwab, S., et al. (2019). Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage. *Neurological Research and Practice, 1*, 12.

13. Prasuhn, J., Brüggemann, N., Hessler, N., et al. (2019). An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: Concept evaluation in a double-blind randomized placebo-controlled parallel group trial. *Neurological Research and Practice, 1*, 31.

14. Gottle, F., Förster, M., Weyers, V., et al. (2019). An unmet clinical need: Roads to remyelination in MS. *Neurological Research and Practice, 1*, 21.

15. Schereth, T. (2020). Guideline, “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft für Neurologie). *Neurological Research and Practice, 2*, 16.

16. Berg, D., Eggert, K., Haslinger, B., et al. (2020). Disease modifying treatment trials in Parkinson’s disease: How to balance expectations and interests of patients, physicians and industry partners? *Neurological Research and Practice, 2*, 31.

17. Eyding, J., Barig, D., Weber, R., et al. (2019). Inpatient TIA and stroke care in adult patients in Germany—Retrospective analysis of nationwide administrative data sets of 2011 to 2017. *Neurological Research and Practice, 1*, 39.

18. Marsh, A. P. (2019). Molecular mechanisms of proteinopathies across neurodegenerative disease: A review. *Neurological Research and Practice, 1*, 35.

19. Diener, H. C., Förderreuther, S., Gaul, C., et al. (2020). Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. *Neurological Research and Practice, 2*, 11.

20. Werner, R., Keller, M., & Woehrle, J. C. (2020). Increased incidence of transient global amnesia during the Covid-19 crisis? *Neurological Research and Practice, 2*, 26.

21. Gövert, F., Leypoldt, F., Junker, R., et al. (2020). Antibody-related movement disorders—A comprehensive review of phenotype-autoantibody correlations and a guide to testing. *Neurological Research and Practice, 2*, 6.

22. Bien, C. G., & Bien, C. I. (2020). Autoimmune encephalitis in children and adolescents. *Neurological Research and Practice, 2*, 4.

23. Stetefeld, H., & Schroeter, M. (2019). SOP myasthenic crisis. *Neurological Research and Practice, 2*, 19.

24. Grobe-Einsler, M., & Kaut, O. (2020). Remarkable improvement of primary orthostatic tremor using perampanel. *Neurological Research and Practice, 2*, 3.

25. Ganti, L., Stead, T., Daneshvar, Y., et al. (2019). GCS 15: When mild TBI isn’t so mild. *Neurological Research and Practice, 1*, 6.

26. Meyding-Lamadé, U., Craemer, E., & Schnitzler, P. (2019). Emerging and re-emerging viruses affecting the nervous system. *Neurological Research and Practice, 1*, 20.

27. Walter, A., & Kraemer, M. (2021). A neurologist’s rhombencephalitis after comirnaty vaccination. A change of perspective. *Neurological Research and Practice, 3*, 56.

28. Stefanou, M. I., Krumbholz, M., Ziemann, U., et al. (2019). Human immunodeficiency virus and multiple sclerosis: A review of the literature. *Neurological Research and Practice, 1*, 24.

29. Rössling, R., & Prüss, H. (2020). SOP: Antibody-associated autoimmune encephalitis. *Neurological Research and Practice, 2*, 1.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more biomedcentral.com/submissions